Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
M117101
- Development stage
- Unknown
- Lead developer
- Maruho
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
M117101 is a topical small molecule muscarinic receptor antagonist being developed by Maruho Co., Ltd. for the treatment of primary palmar hyperhidrosis. As an anticholinergic agent, it functions by competitively inhibiting the binding of acetylcholine to muscarinic receptors on eccrine sweat glands, thereby reducing sweat production. It is currently in Phase II clinical development in Japan, where it is being evaluated as a once-daily topical treatment for patients with excessive palm sweating. This asset is distinct from Maruho's other hyperhidrosis treatments, such as Rapifort (glycopyrronium tosylate) and M518101 (oxybutynin).
02
Targets
mAChR (Muscarinic acetylcholine receptors)
Beyond the preview
Go deeper on M117101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on M117101.